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AIMS AND OBJECTIVES 
 
 
 
 
1. To assess the long term results of pulmonary metastasectomy. 
2. To assess prognostic factors which are likely to influence long 
term outcomes. 
3. To find out a favourable subset of prognostic group who may 
benefit from pulmonary metastasectomy 
 
 
 
 
 
 
 
 
 
 
 
 
 2
 
 
 
PATIENTS AND METHODS 
 
 
 
 
 Between January 1997 to December 2006 , all patients who 
underwent pulmonary metastasectomy were included in this analysis. 
Individual patient data were obtained from the case records in the 
MMTR which also serves as a HBTR for Cancer Institute (WIA). A total 
of 53 patient records were obtained , of that only 42 cases were taken 
analysis. Patients who underwent planned sequential or staged 
metastasectomies were considered to have single metastasectomy and 
redo surgery. 
 
 Analysis was done using SPSS 11.0.1 statistical package. 
Following variables were tested : DFI ,unilateral or  bilateral 
presentation, number of metastases, histological type and site of primary 
tumor, margin status, size of metastases, mediastinal nodes. Survival was 
calculated from the time of first metastasectomy to the last date of follow 
up by means of Kaplan – Meier estimate. 
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REVIEW OF LITERATURE 
 
 
 
 
 After the liver, the lung is the second most common site for 
metastatic involvement in neoplastic disease when all histologies are 
considered. Consequently, 20–54% of patients with cancer will have 
pulmonary metastases at some point in the natural history of their 
disease. In the absence of extrathoracic metastases (approximately 25% 
of patients with disseminated disease), complete resection is associated 
with increased survival, regardless of histology. With appropriate patient 
selection, life expectancy will often be improved with pulmonary 
metastasectomy. Cures are reported, either with resection alone or in 
combination with chemotherapy.[1] [2] Even in the context of 
unresectability, surgical forms of palliation may serve to improve quality 
of life. For other patients (e.g., nonseminomatous germ cell tumors) 
surgery may have a more diagnostic role such as defining residual 
disease potentially amenable to salvage forms of therapy. 
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HISTORY 
 
 
 The first, and perhaps most famous, planned pulmonary 
metastasectomy in the United States was performed in 1933 by Barney 
and Churchill for metastatic renal cell carcinoma[2]. During  the 
nineteenth century there were sporadic reports of lung resections for 
metastatic tumors reported in the European literature. The first one of 
these reports was in 1855, by the French surgeon Sédillot, who removed 
a chest wall tumor and excised disease extending into the lung. 
 
 Almost 30 years later, in 1882, Weinlechner was credited for the 
first resection of a true pulmonary metastases.It was not for another 40 
years that metastasectomy was performed as a separate procedure by 
Divis in Europe.[3] This was followed soon after by similar reports in 
the American literature by Torek and Tudor Edwards in the early 
twentieth century.[4]  
 
 These early reports, and others like them, paved the way toward 
general acceptance of pulmonary metastasectomy. In 1947 Alexander 
and Haight reported the first series of pulmonary metastasectomies.[5] 
By the 1950s there were numerous case series with similar accounts. 
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Today the indications for resection of secondary pulmonary 
malignancies have been broadened to include patients not only with 
recurrent disease, but those with multiple metastases, bilateral lesions, 
and essentially all histologies. 
 
 
PATHOPHYSIOLOGY OF METASTASIS TO LUNG 
 
 
 Tumour spread is a complex process where the eventual outcome, 
in terms of secondary tumour development, depends on the result of a 
number of interactions between the disseminating tumour cell and the 
cells and tissues of the host. There are five major steps involved in 
metastasis, though it should be realized that the process, which is a 
dynamic one, passes from one step to another without interruption while 
a number of steps will be operating concurrently. Breaking the steps into 
a neat sequential series of events therefore gives a sense that there is 
more apparent order to the phenomenon than may actually be the case. 
Following tumour initiation and growth of the primary tumour mass 
(dealt with elsewhere in this volume) there must be:- (1) invasion and 
infiltration of cancer cells into surrounding normal host tissue with 
penetration of small vascular channels or lymphatics; (2) release of 
tumour cells, either as individual cells or as small clumps, into the lumen 
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of the penetrated vessels; (3) survival of the tumour cells in the 
circulation; (4) arrest of the surviving cancer cells in the capillary beds 
of distant organs; and (5) extravasation (or movement out of the lumen 
of the arresting lymphatic or blood vessel), followed by growth, of the 
disseminating tumour cells at the distant site .If all these steps are 
completed the result will be the formation of a secondary tumour in a 
distant organ.[6,7,8]. Hematogenous dissemination through the 
pulmonary arteries, and much less commonly through the bronchial 
arteries or lymphatics, is the most common form of spread for secondary 
pulmonary malignancies. This is thought to be the result of the lung’s 
role as the primary capillary filter for the drainage of most organs. 
Lymphatic spread in pulmonary metastases is unusual and more 
commonly represents hematogenous dissemination with extension to the 
lymphatics. Direct tracheobronchial dissemination is also rare and 
accounts for only 2–5% of pulmonary metastases, most commonly 
associated with renal cell and breast carcinomas. Mediastinal 
involvement is also unusual and is frequently associated with 
concomitant parenchymal spread. 
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Do Metastases Metastasize? 
 
 
 In 1975, Hoover and Ketcham demonstrated, experimentally, that 
metastases do have the ability to metastasize. In their experiment, mice 
had their primary tumor amputated after pulmonary metastasis 
developed. These mice were then placed into parabiosis with normal 
syngeneic partners. Metastases were demonstrated in the non-tumor-
bearing partners. In addition, both autopsy and other experimental data 
have defined the concept of metastases from metastatic disease. It is still 
poorly understood, however, when and how metastases are able to 
metastasize and more importantly how this process can be prevented 
from happening. It is thought that metastases need to follow the same 
steps as the primary tumor to metastasize: angiogenesis, intravasation, 
arrest, and extravasation. 
 
 
Does Lung Cancer Metastasize to Lung? 
 
 
 Lung cancer is able to metastasize via lymphatic channels to the 
ipsilateral lung and, as suggested by some autopsy series, less commonly 
to the contralateral lung. These are patients with one primary lung cancer 
and intrapulmonary metastases. According to the 1997 lung cancer 
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staging revision of the American Joint Commission of Cancer and the 
Union Internationale Contre Cancer, these patients are considered to 
have M1 disease. It is difficult, however, to determine if these patients 
have synchronous lesions or a primary lung cancer with intrapulmonary 
metastases. Ichinose et al have used DNA flow cytometry to evaluate 
these lesions. With this technique, lesions are determined to be 
synchronous if they demonstrate completely different DNA ploidy. If 
both tumors show diploidy or when at least one DNA index of abnormal 
clones between two aneuploidy tumors 
 
 
SYMPTOMS AND PRESENTATION 
 
 
 Approximately 75–90% of patients with secondary pulmonary 
malignancies are asymptomatic and, therefore, their disease is most 
commonly discovered incidentally on routine or follow-up radiological 
examinations.[8]  Symptoms, when they do occur, typically result from a 
delayed diagnosis with endobronchial or pleural involvement, large 
bulky disease, or central tumors. Patients may present with cough and 
hemoptysis suggesting an endobronchial lesion and thus warranting 
bronchoscopic examination. Endobronchial metastatic lesions are 
extremely rare, less than 2%, in patients who die of solid tumors with 
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breast, kidney, pancreas, colon, and melanoma as the most common 
sources.Another presenting symptom may be dyspnea, which is usually 
secondary to airway obstruction, a pleural effusion, parenchymal 
replacement by multiple metastatic lesions, or lymphatic spread. Finally, 
chest pain, wheezing, or pneumothorax may be other modes of 
presentation. 
 
 
RADIOGRAPHIC APPEARANCE 
 
 
 Every patient with a history of cancer should be routinely 
followed up and depending on the primary tumor with a plain CXR 
and/or a computerized assisted tomography (CT) of the chest. The 
presence of a new solitary pulmonary nodule in a patient with a prior 
malignancy essentially confirms the diagnosis of cancer. In one study in 
which 800 extrathoracic cancer patients presented with a new solitary 
pulmonary nodule, 87% were found to have a malignancy (63% primary 
lung cancer, 24% metastatic disease).[9] The likelihood of finding 
metastases in a cohort of patients, all with no known cancer, therefore, is 
even lower. In one such study only 3% of solitary pulmonary lesions in 
887 such patients were metastatic.[10]. 
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 Once a nodule has been found on a CXR, in a patient with a 
history of previous extrathoracic cancer, a diagnostic dilemma exists in 
determining whether the lesion represents metastatic or primary disease. 
This distinction has significant implications with respect to treatment and 
prognosis.The likelihood that a given pulmonary nodule is metastatic is 
dependent on the histology of the primary tumor  .[9]. 
 
 Metastatic lung nodules themselves are most commonly described 
as being well circumscribed with smooth margins and spherical shape as 
well as located in the periphery of the lung[11]  . In addition, there is a 
predilection for a more basilar distribution consistent with this region’s 
increased blood flow in the upright position.Irregular borders and 
associated linear densities are more frequently associated with primary 
bronchogenic lung cancer.[11] 
 Primary malignancies most commonly metastatic to the lung are 
carcinomas of breast colon kidney uterus prostate and oropharynx. 
Tumors with the highest predilection for pulmonary metastases are 
choriocarcinoma osteosarcoma testicular tumors melanoma Ewing’s 
sarcoma and Kaposi’s sarcoma. 
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 Approximately, 70–80% of tumor nodules less than 6 mm will be 
detectable by CT of the chest. In addition, CT scan may further define 
the number and location of the nodules, aiding in assessment of 
resectability. However, modern high-resolution CT scan techniques are 
able to detect lesions in the 2–3 mm range that are often difficult to be 
palpated during thoracotomy.  
 
 In addition to CXR and CT scan, other imaging modalities such as 
magnetic resonance imaging (MRI) may also be of use when assessing 
resectability and attempting to visualize potential involvement of the 
spine or surrounding structures.[12] The resolution of this study, 
however, is still inferior to CT. Positron emission tomography (PET) 
scans may have a role in characterizing metastatic pulmonary nodules, 
for breast carcinoma, colorectal tumors, and cholangiocarcinomas.  
Spiral CT has been shown to be superior to PET scans in diagnosing 
metastases from primary bone tumors (i.e., osteosarcomas and Ewing 
sarcomas)[13]. Occasionally, nuclear radiological techniques are useful 
in determining lung metastases from thyroid tumors as well as other 
neuroendocrine tumors.  
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CRITERIA FOR SURGICAL RESECTION 
 
 
 In chemo-sensitive tumors clinical experience has allowed 
identification of criteria by which to select patients for surgical resection. 
Most important of this is how effective chemotherapy is for a particular 
type of cancer. A secondary factor is whether the natural history of that 
cancer is to metastasize predominantly to lungs or to disseminate widely. 
Two types of cancer which illustrate the development of improvements 
in chemotherapy are breast cancer and germ cell cancer. 
 
 Most solid tumors that metastasize to the lung are insensitive to 
currently available chemotherapy. Pulmonary  resection is an important 
primary form of treatment for these malignancies , which include 
colorectal ,some gynaecological cancers, head and neck cancers, 
malignant melanoma and osteogenic and soft tissue sarcomas. 
 Consistently important criteria include the following – (1) control 
of the primary tumor or ability to resect primary tumor completely 
simultaneously with resection of metastases,(2) ability to resect 
metastatic disease completely;(3) absence of extrathoracic metastases 
;(4)ability of the patient to withstand the procedure ; and (5) absence of 
better alternative systemic treatment.the criteria found to be important in 
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select series are DFI, tumor doubling time , number of pulmonary 
metastases. The criteria for surgical resection will evolve with better 
understanding of tumor biology, with better systemic treatment. Majority 
of the patients relapse and require systemic treatment. 
 
 
TECHNIQUE OF PULMONARY RESECTION 
 
 
 The ojective is to remove all  gross tumor while preserving as 
much as normal parenchyma as possible. Most of them are small , 
discrete , sub pleural nodules that can be easily removed by wedge 
resection using GIA or TA stapler. If not accessible by stapler , it can be 
excised by needle tip electrocautery. Usually the preferred margins are 
0.5 to 1.5 cm of normal lung all around. Laser can also be used to 
accomplish wedge resections, but it carries no advantage over needle tip 
electrocautery. Argon plasma coagulator may be helpful in obtaining 
haemostasis . 
 For larger lesions or centrally located lesions  may  require 
lobectomy or pneumonectomy procedures for their complete removal , 
but such resections donot increase the chance of cure after 
metastasectomy. They may offer long time survival and hence such 
extensive procedures should be considered carefully as these patients 
may develop subsequent lesions in the remaining lung.  
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 Approaches to metastasectomy may be either a thoracotomy , or 
median sternotomy or clam shell thoractomy for bilateral lesions. 
Minimally invasive procedures like video assisted thoracoscopic surgery 
,VATS has also  been advocated . but the procedure lacks the tactile 
sensation , and its imperative that the surgeon systematically inspect and 
palpate the entire lung to ensure complete removal of all  tumor. 
Therefore most thoracic oncologists limit VATS to  diagnosis and 
staging of pulmonary metastases. 
 
 Role of lymph node dissection in the management of pulmonary 
metastases has not been defined. Lymph node involvement is 
occasionally seen and may be associated with poorer long term survival, 
but the implications in patient management are unclear. Systematic 
lymph nnode dissection is not recommended, only suspicious nodes be 
resected in the interests of proper diagnosis and for resecting all gross 
disease.  
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  Lateral 
Thoracotomy
Median 
Sternotomy
Clamshell VATS 
Advantages Familiar 
approach; 
optimum 
exposure to 
hemithorax 
One 
operation 
accesses and 
treats 
bilateral 
disease; 
good 
exposure to 
anterior 
mediastinum 
Good 
exposure to 
hemithoraces 
and to entire 
mediastinum
Low 
morbidity; 
good 
exposure to 
lung surface 
and pleural 
space  
Disadvantages Bilateral 
disease 
requires 2 
procedures 
Limited 
exposure to 
left lower 
lobe 
Higher 
morbidity; 
longer 
operating 
time 
Lesions 
below lung 
surface 
difficult to 
locate; no 
palpation of 
lung  
Relative 
patient 
discomfort 
+++ ++ ++++ + 
Special 
considerations 
A lung 
without 
evidence of 
disease on 
imaging will 
not be 
explored  
Use with 
caution in 
patients who 
may not 
tolerate 
traction on 
the heart  
Problem 
with 
malunion of 
sternum 
Reserve for 
patients with 
minimal, 
easily 
accessible 
disease and 
long DFI  
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RESULTS OF PULMONARY METASTASECTOMY 
 
 
 Pulmonary metastasectomy in appropriately selected patients has 
been shown to improve survival. When all histologies are considered, the 
5-year survival rates for patients undergoing resection of secondary 
pulmonary malignancy are 25–35%. In an attempt to more clearly define 
those patients most likely to benefit from metastasectomy, many series 
have evaluated potential prognostic indicators. For example, short tumor 
doubling time is frequently a sign of an aggressive lesion. It has been 
proposed that patients with such tumors, therefore, might not derive a 
survival benefit from resection. Reports of such studies, however, are 
equivocal. Moreover, the practical application of such a measurement is 
difficult. Disease-free interval has also been studied in an attempt to 
predict outcomes. Longer disease-free intervals, however, have not been 
consistently associated with a better prognosis. An increased number of 
nodules seen on preoperative testing might intuitively be associated with 
a poor prognosis. In general, patients with multiple nodules do more 
poorly then those with a solitary nodule. Again, however, there is great 
variability.  
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Histology 5-year survival without metastasectomy 5-year survival 
with metastasectomy 
 
All histologies25–40% 
Breast cancer -  35–50%  
Colorectal cancer -  40–45%  
Germ cell tumors 68% 
Head and neck squamous cell carcinoma 29–60%  
Melanoma - 21–36% 
Osteosarcoma - 20–40% 
Renal cell carcinoma - 13–54% 
Soft tissue sarcomas - 20–40% 
Urinary tract cancer - 25–43% 
 
 The number of nodules above which resection is unwarranted is 
also unclear. As many as 20–30 metastasectomies can be performed at 
one operation with good results. In addition, the number of nodules 
estimated with preoperative testing is often inaccurate. As such, 
multiplicity may be more appropriately used to assist in the assessment 
of tumor resectability. None of these criteria for predicting positive 
outcome from metastasectomy has been universally established. Most 
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studies have proposed that complete resectability is the only universal 
determinant of prognosis across all histologies. 
 
 Many of the aforementioned studies attempting to evaluate 
prognostic determinants in pulmonary metastasectomy have been faulted 
for insufficient statistical power. One group, however, reported 5206 
cases of pulmonary metastases from various sites from the 18 medical 
centers of the International Registry of Lung Metastases. In this 
retrospective review, three parameters were shown to have prognostic 
significance regardless of primary histology: resectability, a disease-free 
interval of over 36 months, and solitary versus multiple metastasis. As a 
result, they have proposed a four-group staging system based on the 
number of poor prognostic indicators present in a given . Although 
staging systems such as this one may better define those patients most 
likely to benefit from metastasectomy, survival in patients following 
surgery, even with poor prognostic indicators, is superior to any other 
treatment. Consequently, some feel that metastasectomy should be 
offered to appropriate patients regardless of these factors, with the 
possible exception of inability to perform complete resection. 
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 In addition to the aforementioned factors equivocally associated 
with prognosis, other factors have been clearly shown not to affect 
outcome. These factors include unilateral versus bilateral disease, age, 
gender, and wedge resection versus formal lobectomy. 
 
 Recurrence is the most common cause of death following 
complete pulmonary resection of metastatic disease. Despite this, repeat 
resections have contributed to prolonged survival for a number of 
histologies. The most studied of these is soft tissue sarcomas. In a study 
by the National Cancer Institute in which patients underwent reresection 
for softtissue sarcomas, no difference in the actuarial 5-year survival was 
found in those undergoing one, two, and even three resections for 
recurrence. Preoperative selection criteria similar to those utilized with 
the initial resection are important in appropriately choosing patients for 
repeat resection. This ensures the absence of disseminated disease and 
the ability of a given patient to tolerate the proposed procedure. Once 
screened, therefore,resection of recurrent disease will be offered to the 
majority of patients (approximately 70%) should no extrathoracic 
dissemination be present and should the lesion be amenable to resection. 
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METASTASES TO THE LUNG 
 
Osteosarcoma 
 
 
 Like soft tissue sarcomas, osteosarcoma has a strong predilection 
for metastasis to the lung. In addition, the lesions themselves are 
frequently multiple and often recur despite resection. Consequently 
pulmonary involvement is responsible for the majority of deaths in 
patients with this disease. Approximately 10–20% of patients will have 
distant metastases on initial evaluation, and, as with other histologies, 
CT of the chest is the imaging modality of choice for detection. 
 
 Prior to the introduction of chemotherapy, the overall survival 
from osteogenic sarcoma was only 10–20%.[14]  In the early 1970s, 
however, the use of chemotherapy, especially high-dose methotrexate, 
substantially improved outcomes.[15] Later, with the introduction of 
multimodality therapy, chemotherapy (doxorubicin, high-dose 
cyclophosphamide, and cisplatin) combined with resection, improved 5-
year survival rates to 32–40%. [16]  
 
 Most studies conclude that complete surgical resection is 
associated with increased survival. [18] 
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Soft Tissue Sarcoma 
 
 
  Most soft tissue sarcomas metastasize within the first 2 years of 
diagnosis, with the lungs being the most common site (80–90% of the 
time). Consequently, secondary pulmonary disease is the primary cause 
of death in these patients. The predilection for dissemination to the lungs 
also emphasizes the importance of pulmonary surveillance in following 
up sarcoma patients.  
 
 Of those with soft tissue sarcomas, however, 20% will have 
isolated disease and are candidates for resection. Unlike pulmonary 
metastases from melanoma and carcinoma that are commonly solitary, 
sarcomatous involvement of the lung tends to be multiple. Five-year 
survival rates following resection of secondary pulmonary disease are 
20–30%, a significant improvement over those patients who are not 
resected.[19] 
 
 A large retrospective study from Memorial Sloan-Kettering 
reviewed 3149 patients with soft tissue sarcomas. Of these patients, 719 
developed pulmonary metastases, and 248 underwent at least one 
pulmonary resection. Three independent negative prognostic factors 
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were identified: three or more lesions, largest metastases’ diameter more 
than 2 cm, and high-grade primary tumor histology.[20] A much smaller 
study, including 23 patients, found similar prognostic factors associated 
with poor outcomes. These included three or more lesions and disease-
free interval of less than 6 months 
 
 
Colorectal Carcinoma 
 
 
 The incidence of colorectal carcinoma in the United States is high, 
with approximately 100,000 new cases occurring each year. 
Approximately, 10–30% of these patients will go on to have metastases. 
Because of this high incidence of recurrence it is important to follow up 
these patients very closely. The most common extraabdominal location 
of secondary disease is metastasis to the lung. Unfortunately, such 
pulmonary involvement is also frequently associated with disseminated 
disease, usually involving the liver. Ten percent of colorectal cancer 
patients with metastatic involvement of the lung, or 1–3% of those with 
colorectal cancer, will have isolated pulmonary disease [21,22]. These 
patients benefit from resection. [21] Five-year survival rates following 
resection of colorectal metastases to the lung are 20–40% and 10-year 
survival is 20%.[21]. In several series examining this issue, the 5-year 
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survival rates following dual metastasectomy have been reported to 
range from 21 to 52%.In addition, patients who develop a pulmonary 
recurrence after a hepatic resection for colorectal metastases appear to 
benefit from pulmonary metastasectomy. [23] The only positive 
prognostic factors that are consistent among four recent series of patients 
after pulmonary metastasectomy for colorectal metastases are complete 
resection and a normal CEA level prior to thoracotomy.[24] 
 
 
Breast Carcinoma 
 
 
 Breast cancer accounts for 30,000 deaths each year and is 
currently the second most common cause of cancer deaths in females in 
the United States, behind lung cancer. Pulmonary involvement in breast 
cancer is most commonly associated with widespread disease, thereby 
contraindicating resection in the majority of patients. A thorough 
preoperative workup, specifically searching for extrapulmonary disease, 
is necessary in considering patients for pulmonary resection. When 
properly screened, up to 20% of patients will be found to have isolated 
pulmonary disease and may potentially benefit from metastasectomy. 
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 Considering that a pulmonary nodule in a patient with known 
breast carcinoma is more likely to be primary lung cancer,[25] 
histological diagnosis is needed to proceed with appropriate 
management. A diagnosis of adenocarcinoma on biopsy obtained by 
FNA or wedge resection, however,requires the use of further  assays 
(e.g., ER/PR receptor status and cytokeratin stains) to establish a 
diagnosis of breast cancer. [26] 
 
 Five-year survival rates after metastatic resection range from 35% 
to 62%. [27] Despite these results, high-dose multidrug chemotherapy 
and bone marrow rescue are the primary forms of treatment currently 
offered to patients with disseminated pulmonary involvement. Patients 
with ER-receptor-positive metastases and/or complete resection appear 
to have a more favorable prognosis. 
 
 
Germ Cell Tumors 
 
 
 Germ cell tumors account for only 1% of all cancers, but are the 
most common malignancy in males between 15 and 35 years of age. The 
most common site of distant metastasis for these tumors is the lung. 
Overall, greater then 90% of germ cell tumors will be cured with 
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cisplatin-based chemotherapy and, therefore, the primary treatment is 
nonsurgical. Of those patients with nonseminomatous germ cell tumors 
with pulmonary metastases, 70% will have normalization of tumor 
markers and radiolographic clearance of disease, a complete response, 
following chemotherapy. Patients with residual radiographic evidence of 
pulmonary involvement, despite normal serum markers (AFP, hCG-) 
after chemotherapy, are frequently referred for resection to determine if 
viable tumor exists in these partial responders and nonresponders. Of 
those who do not respond to initial chemotherapy, 25% will respond to 
salvage forms of treatment. In addition, patients with radiological 
evidence of disease and abnormal serum markers may also be candidates 
for surgical salvage if their disease is considered resectable. Because no 
reliable method of preoperative diagnosis exists, and the potential for 
malignant and chemoresistant degeneration of benign teratomas may 
occur, resection of any residual disease is indicated. [28]  
 
 Controversy exists surrounding the appropriate management of 
residual pulmonary masses found in seminoma patients following 
chemotherapy. Less then 25% of such residual disease will represent 
viable tumor and less than 5% will reveal teratoma. For this reason, and 
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the morbidity associated with resection, expectant management is 
advocated by some. For patients with larger masses, radiation therapy, as 
the only treatment or preceded by resection, may be indicated.[28] 
 
 
Melanoma 
 
 
 Melanoma is responsible for 1–2% of cancer deaths. The lung is 
involved in secondary disease 15% of the time. [29] Although the lungs 
are one of the most common sites of distant spread, only 5% of patients 
with such involvement have an absence of extrathoracic involvement. 
More commonly, lesions found on CXR are a manifestation of 
widespread disease at the time of diagnosis and such patients are 
traditionally treated with chemotherapy. A thorough search for 
dissemination is indicated in melanoma patients being considered for 
resection. Although melanoma does have the lowest 5-year survival rate 
following metastasectomy,[30]  long-term survival benefits have been 
reported in many cases. Thus, the surgeon may wish to apply more 
rigorous criteria in selecting patients with melanoma for pulmonary 
metastasectomy.[31] 
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 Leo et al reviewed 328 patients identified in the international 
registry of lung metastases who underwent resection of melanotic 
pulmonary metastases.[32] Of these patients, 282 underwent complete 
resection. Independent unfavorable prognostic factors included multiple 
metastases and time to pulmonary metastases of less than 36 months. 
 
 
Head and Neck Squamous Cell Carcinoma 
 
 
 Forty percent of patients with head and neck squamous cell 
carcinoma will go on to develop distant disease. In these patients the 
lung is the most commonly affected organ. Some of the same risk factors 
that predispose patients to head and neck cancer also put patients at risk 
for primary cancer of the lung. As a result, a solitary nodule found in 
follow-up is more likely to be primary lung cancer. For this reason, these 
lesions should be treated as such until proven otherwise. Five-year 
survival rates following metastatic resection range from 29 to 60%.[33] 
Positive prognostic factors include single lesion, disease-free interval of 
more than 2 years, locoregional control, and complete resection. [33]  
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Urological Tumors 
 
 
 Of approximately 30,000 patients diagnosed with renal cell 
carcinoma each year, 60–70% will go on to develop metastases. The 
most common metastatic site is the lung. Unresected, less than 5% of 
patients will survive 5 years. In contrast, after complete pulmonary 
metastasectomy 5-year survivals range between 37 and 54%. [34] 
Positive prognostic factors include complete resection, disease-free 
interval of more than 2 years, and fewer than seven lesions. In view of 
these results, and the fact that renal cell carcinomas are chemoresistant 
and radioresistant, surgical resection of pulmonary metastases is 
indicated for most cases.[35] 
 
 Of patients with transitional cell carcinoma 50% will also develop 
pulmonary metastases. Although reports in the literature are sparse, 
isolated disease, when completely resected, may result in 5-year survival 
rates of approximately 25%. 
 
 
Endocrine Tumors 
 
 
 Pulmonary metastases from these tumors are rare. Occasionally 
resection may be indicated to alleviate symptoms of hormone 
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production.A review of 25 patients who underwent pulmonary 
metastasectomy for different types of endocrine tumors showed a 61% 5-
year survival.Independent predictors of poor survival included positive 
mediastinal lymph nodes, incomplete resection, and short disease-free 
interval.[36] 
 
 
Gynecological Tumors 
 
 
Uterine and cervical cancers have also been shown to respond to 
metastasectomy in appropriate candidates. A 24–52% 5-year survival 
following pulmonary metastasectomy has been reported.[37] For 
choriocarcinoma multidrug chemotherapy is the primary form of 
treatment.Resistant lesions should be considered for resection. Five-year 
survival rates approaching 50% have been reported.[38]  
 
 
ALTERNATIVE FORMS OF THERAPY IN SECONDARY 
PULMONARY DISEASE 
 
Isolated Lung Perfusion 
 
 
 Systemic toxicity of chemotherapeutic agents frequently limits the 
dose that would otherwise eradicate micrometastatic disease in the lung. 
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Isolated regional lung perfusion therapy is a novel form of delivery that 
has shown some promise. This technique is analogous to isolated limb 
perfusion, a therapy used in the treatment of advanced sarcoma and 
melanoma. The nearly closed nature of the pulmonary circulation, with 
only 5% being perfused by the bronchial circulation, makes the lung an 
ideal organ for isolated perfusion. Isolated lung perfusion has been 
applied to a number of histological types including colorectal 
carcinomas, sarcomas, melanoma, and renal cell carcinoma. Eight 
patients with unresectable pulmonary metastases from soft tissue 
sarcomas were enrolled in a Phase I trial that demonstrated that the 
technique was safe and feasible but none of the patients responded to the 
therapy.[39]  
 
 
Lung transplantation 
 
 
 The ideal solution for treating patients with unresectable 
metastatic cancer to the lung is to entirely remove the diseased organ and 
replace it with healthy lung. The patient must not have tumor elsewhere, 
either at the primary tumor site or other metastatic sites. Although this 
can never be determined with certainty, a long disease-free interval at all 
sites except the lung and a thorough metastatic workup are encouraging. 
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In this context the indication for lung transplantation would be oncologic 
rather than respiratory. Thus, it would be potentially curative treatment 
for localized disease, not replacement of a failed organ.  
 
 Solid-organ transplantation for cancer therapy is a proven concept. 
In patients with hepatocellular carcinoma who have either one tumor 
mass less than 5 cm in diameter or up to three nodules smaller than 3 cm, 
the survival at 5 years after liver transplantation is 70% and the 
recurrence rate is approximately 15%.[46] The experience with lung 
transplantation for cancer is small and not nearly so promising. de Perrot 
et al. summarized the world experience with transplantation for 
bronchioloalveolar carcinoma. Of 26 reported transplants, 13 have 
recurred, 11 of which were in the transplanted lung.[46]  
 
 
Radiofrequency Ablation 
 
 
 Radiofrequency ablation (RFA) delivers thermal energy through a 
catheter delivery system resulting in coagulation necrosis. This technique 
may be used in the management of metastastic disease to the lungs. 
Further studies investigating the role of this technique are needed. 
 
 32
Palliative Therapy 
 
 
 Palliative therapy should be considered for symptomatic patients 
whose disseminated disease or unresectability precludes curative forms 
of therapy. Endobronchial lesions are frequently symptomatic. 
Commonly they are associated with unresectable disease and frequently 
require palliative therapy. Those patients with endobronchial lesions who 
present with hemoptysis may respond well to a short course of external 
beam radiation. 
 
 Obstructive lesions may be treated bronchoscopically with 
mechanical debridement, laser ablation, brachytherapy, or stenting. 
Nd:YAG laser provides the best penetration, coagulation, and thermal 
necrosis and may be administered through a flexible fiberoptic system. 
 
 
Photodynamic therapy  
 
 
 Photodynamic therapy (PDT) is a technique for killing cells that 
employs nontoxic compounds, photosensitizers, that tends to concentrate 
in tumor cells and can subsequently be activated with visible light. When 
the photosensitizer is exposed to the correct wavelength of light, it has 
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the ability to transfer energy to oxygen. It is the excited species of 
oxygen that eventually cause cell death. PDT is thought to work by both 
direct tumor cell kill as well as destruction of the tumor’s 
neovascularization. PDT is currently approved for obstructing as well as 
early stage endobronchial lesions and, in select cases, may be a good 
option. 
 
 
Other supportive measures 
 
 
 Malignant effusions secondary to neoplastic disease may be 
voluminous and consequently symptomatic. When they occur, they may 
be treated by VATS or bedside drainage followed by talc pleurodesis. 
Internal shunting or external drainage of a pleural effusion is an option 
for a failed pleurodesis or, occasionally, as the primary palliative 
procedure.  
 
 Pericardial effusions occurring in the setting of disseminated 
disease may become symptomatic. Percutaneous drainage, subxiphoid 
window, or VATS window procedures are the options for this condition. 
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COMPLETENESS OF RESECTION (R0 Vs R1) 
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DISEASE FREE INTERVAL (DFI) 
 
1- DFI  0 To 11 Months 
2- DFI  12 To 35 Months 
3- DFI > 36 Months 
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NUMBER OF METASTASES 
 
1. 1 Single Mets 
2. 2 To 3 Mets 
3. > 4 Mets 
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TYPE OF TUMOR 
 
1. OSTEOSARCOMA 
2. SOFT TISSUE SARCOMA 
3. RECTUM 
4.  OTHER EPITHELIAL TUMORS 
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SIZE OF THE METASTASIS 
1. < 1 cm 
2. 1.1 to 4 cm 
3. > 4 cm 
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MEDIASTINAL NODES 
 
1. Node negative  
2. Node positive 
 
Survival Functions
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UNILATERAL OR BILATERAL PRESENTATION 
 
1- Unilateral 
2- Bilateral 
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PROGNOSTIC GROUPING 
 
1. Group I – Resectable, no risk factors (DFI > 36 months and 1 
metastases) 
2. Group II (DFI < 36 months or multiple metastases)  
3. Group III (DFI <36 months and multiple metastases) 
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RESULTS 
 
 
 
 
 A total of 53 patients underwent pulmonary metastasectomy , of 
which only 42 patient records were taken for analysis. The rest 11 
patients were excluded based on various reasons , benign pathology (5), 
different histology (3), unresectable disease (3). These 42 patients 
underwent 45 metastasectomies (3 for recurrent disease). Staged bilateral 
metastasectomy was considered as single procedure. Survival was 
calculated from the time of first metastasectomy to the last date of follow 
up. Average follow up was 28 months (range 4 months to 84 months).13 
patients were lost to follow up after a variable period of follow up 
ranging from 19 months to 60 months (average – of 32 months). 
 
 
Patient features  
 
 
 Overall there were 23 males (54.7%), and the mean age was 31 yrs 
(median 28 yrs , range 13 -64 yrs). Sarcomas , both soft tissue and 
osteogenic constituted 62 % of pulmonary metastasectomies ( 
osteosarcoma – 33%, sarcoma – 29%), and the rest comprised of 
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epithelial tumors (33%, which includes various subsites like breast , 
parotid , cervix , endometrium, testis and rectum [14 %] ) and other sites 
(2 patients 4%, Giant cel tumor of bone  and choriocarcinoma). In the 
whole series the , 26% ofpatients had DFI of 0 to 11 months, 33% had 
DFI of 12 to 36 months and 41 % had DFI of > 36 months. The median 
DFI was 31.3 months. Most common presentation was unilateral (86%) . 
The surgical approach was monolateral thoracotomy in 86 % and 
bilateral staged thoracotomy in 14 %. For large majority of tumours 
wedge resections ( 71%) , were the procedure most commonly done, 
lobectomies (29 %) unilobar or bilobar were usually done for large 
lesions or centrally placed  lesions not amenable to wedge resections. 
 
 On the basis of pathological analysis 57% of patients had only 
single metastases, 33% had 2 to 3 metastases and around 10% had > 4 
metastases. The resections were complete (R0) in 88% and R1 in 12 %. 
The maximum numbers of metastases were 22 in one patient with 
NSGCT of testis. 
 
 Majority of the metastases were of size between 2 to  4 cm 
(69%),lesions less tha 1 cm and  more than 4 cm accounted for 10% and 
21 % respectively. 
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 Lympnodal dissection was done in 9 cases of the total 12 
lobectomies and metastases to these lymph nodes were found in only 2 
cases. 
 
 6 patients reccured of which only two patients underwent redo 
metastasectomy. 
 
 
Survival  
 
 
 There were no operative mortality in the entire cohort of patients. 
The overall survival irrespective of the type of primary in this study was 
66% at 5 years. 
 
 The following variables were tested for assessing the impact on 
prognosis: 
 
 
Completeness of resection (R0 Vs R1) 
 
 
 The overall survival was 82% at 36 months  for patients with R0 
resection. In patients who had R1 resection , none of them survived 
beyond 45 months , overall survival was only 20% at 36 months. This 
difference was not found to be significant in both univariate and 
multivariate analysis using Cox regression analysis. 
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Disease free interval (DFI) 
 
 
 For patients with a DFI of 0 to 11 months, the  overall survival 
was 72% at 36 months. For patients who had DFI of 12 to 35 months the 
overall survival was 76 % at 36 months . Patients who had DFI > 36 
months  the overall survival was 76% at 36months.  This was also tested 
tested for significance in both univariate and multivariate analysis using 
Cox regression analysis and was not found to be significant. 
 
 
Number of proven metastases 
 
 
 Patients with single metastases had survival of 82.5% and 69% at 
36 months and 60 months respectively.  For the patients who had 2 to 3 
metastases the survival was 61% at 36 months, and  as no further events 
occurred beyond this, survival at 60 months could not be calculated. In 
patients who had > 4 metastases the survival was 75% at both 36 months 
. This variable also was not found to be significant in both univariate and 
multivariate analysis. 
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Histological type of tumor 
 
 
 The overall survival among patients with osteosarcoma was 
76.7%at 36 months. In patients with metastatic soft tissue sarcoma was 
72.3% at 36 months. The overall survival in patients with metastatic 
rectal tumors was 66.7% and 64.8% in patients with other epithelial 
carcinoma at 36 months respectively. 
 
 
Mediastinal nodes  
 
 
 In patients who had positive mediastinal nodes none of them 
survived beyond 10 months. While in patients who where node negative 
76% survived at 36 months and 40% at 60 months respectively. 
 
 
Unilateral and bilateral metastases 
 
 
 The survival in patients who had unilateral metastases was 76.5% 
and 64.8% at 36 months and 60 months respectively, while patients who 
had bilateral metastases the survival was 65.6 % and 64.8% at 36 months 
and 60 months respectively this was also not found to be significant in 
univariate and multivariate analysis. 
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Size of the metastases 
 
 
 Survival among patients who had lesions less than 1 cm were 75% 
at 36 months, while larger lesions >4 cm and lesions 1 to 4 cm had 
survival of 65% and 70% respectively. However in both univariate and 
multivariate analysis this not found to be significant. 
 
 
Recurrence  
 
 
 6 patients (14%) recurred within a mean period of 20 months 
(range 2 to 50 months). Only 3 patients underwent redo metastasectomy 
and all three had a mean survival of 34 months (range 22 to 50 months) 
and only one expired , however all patients who did not undergo 
metastasectomy expired within a mean period of 4 months. 
 
 
Prognostic grouping 
 
 
 A prognostic group was made based on number of metastases and 
DFI. They were considerd low risk Group I – Resectable , no risk factors 
(DFI > 36 months and single metastases), intermediate risk , Group II 
(DFI < 36 months or multiple metastases) , and high risk, Group III (DFI 
<36 months and multiple metastases). In patients who where in Group III 
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the survival was 65% at 36 months , in Group II there was 75% survival 
at 36 months and 50 % at 60 months respectively , and in patients with 
Group I the survival of 88% at 36 months. This was also not found to be 
significant in both univariate and multivariate analysis.  
 
 
Post operative mortality and complications 
 
 
 There was no 30 day post operative mortality and only 6% 
morbidity (3 patients, 2 were cardiac events in the form of SVT, and the 
other was pulmonary which required postoperative mechanical 
ventilation). 
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DISCUSSION 
 
 
 
 
 The benefit of pulmonary metastasectomy is still questioned by 
physicians because patients are offered this treatment to a highly select 
group of patients and on a highly individualized basis depending on the 
philosophy and policy of the treating physician and the institute. The 
prognosis of these patients without surgical resection is still fully not 
known and its unlikely that the benefit of surgical resection compared 
with supportive care alone could alone be defined in randomized manner 
prospectively. Marcove et al documented that the natural history of 
unresected pulmonary metastasis was associated with 50% mortality at 1 
year, 88% mortality at 2 years,95% at 3 years and none survived 5 years 
[40]. With improved medical and surgical treatments it has been possible 
now to attain a 5 year survival of 50% [41]. 
 
 In this study the overall survival in the entire cohort of patients 
was 66% at 5 years which is higher than seen in the literature (34% at 5 
years) because of the selection bias and small number of patients [42]. 
There was a tendency to offer metastasectomy to patients who had 
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longer disease free interval as can be seen in our frequency of DFI where 
almost 74%  of patients had DFI of  greater than 12 months and among 
them majority had DFI of greater than 36 months (41%). Other problem 
in this study was about 30 % of the patients were to lost to follow up 
after an average time of  32 months (range 19 to 60 months) , hence 
information on events beyond this was unavailable so as to give a 
meaningful survival figures at 5 years. Though the variables like 
decreasing DFI , increase in no of metastasis, increase in size of lesion, 
R1 resections, bilateral presentation and mediastinal lymphnode 
positivity were associated with decreased survival at 3 years ,these were 
not found to be significant in univariate or multivariate analysis using 
Cox regression analysis.   
 
 Epithelial tumours had lower survival at 3 years in comparison 
with sarcomatous tumours which is also in occurrence with the 
literature[41]. Patients with  osteosarcoma had longer survival  than soft 
tissue sarcoma at 36 months after metastasectomy ( 76% and 72% 
respectively). The reasons may be multifactorial, like chemotherapy 
offered for patients who had synchronous metastases, and probably 
because of the inherent natural history of the lesion developing after a 
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long DFI. Also it is a fact that synchronous metastases in osteosarcoma 
need not represent a more aggressive disease, which is however not true 
in patients with epithelial cancer. 
 
 Our attempt to identify a good prognostic group based on the risk 
factors like completely resected lesions, DFI and number of metastases 
was not successful as it failed to show significance in univariate and 
multivariate analysis, though there was difference in survival between 
good risk and poor risk groups (88% and 65% at 36 months). 
 
 Another observation in this study was in patients who recurred 
after metastasectomy and could undergo a R0 redo metastasectomy, had 
an average survival of 34 months (22 to 50 months) in comparison to 
patients who could not undergo metastasectomy as none of them 
survived beyond 7 months (mean of 4 months). This was also observed 
in the International Registry of Lung Metastasis study [41]. This good 
survival observed in patients who underwent redo metastasectomy can 
be explained by the inherent biology of the lesion as these patients had 
an average time to recurrence of 22 months (15 to 41 months) 
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 However in spite of all these shortcomings it can be confirmed 
that metastasectomy is a potentially curative treatment that can be done 
safely with low mortality or morbidity. In our series there was no 30 day 
post operative mortality and only 6% morbidity (3 patients, 2 were 
cardiac events in the form of SVT, and the other was pulmonary which 
required postoperative mechanical ventilation). 
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CONCLUSIONS 
 
 
 
 
1. Pulmonary metastasectomy is a potentially curative treatment that 
can be done safely with low mortality or morbidity.  
2. Good prognostic variables like increasing DFI (> 1 year), ability 
to do R0 resection, solitary metastasis, size of the lesion less than 
1 cm, and absence of mediastinal nodal positivity showed a trend 
towards improved survival. Good prognostic group selected on the 
basis of the risk factors like completely resected lesions, DFI and 
number of metastases show a difference in survival between good 
risk and poor risk groups ( 88% and 65% at 36 months). Although 
these were not found to be significant in univariate or multivariate 
analysis using Cox regression analysis. 
3. There is a need for larger multicenteric analysis of data with larger 
duration of follow up, from specialized centres who practice 
pulmonary metastasectomy, to arrive at definite conclusions. 
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